-

Innovation in Biological Samples Transportation: Cerba HealthCare Successfully Performed the First Flight With Drone in France and Italy

  • A low-carbon logistic option that should avoid traffic-related delays while covering remoted places in the country
  • Shortens time-to-results and improves patient management regardless of location

ISSY LES MOULINEAUX, France--(BUSINESS WIRE)--Cerba HealthCare, a leading global player in medical diagnosis, has been exploring new alternatives to transport biological samples that combine low carbon footprint, shorter time-to-results for patients and prescribers while allowing every patient to benefit from the analytical quality of large capacity laboratory platforms in a timely manner.

Over the past couple of weeks, France and Italy, two major affiliates of the Group, hosted drone-enabled sample transport and successfully performed their experimental flights in different conditions.

Jérôme Sallette, Chief Scientific Officer at Cerba HealthCare, comments: “Following the use cases we described in our white paper, the drone flight we experimented in Normandy with Cerballiance is a first step toward a broader and more sustainable approach of our logistic mix for sample transportation. It illustrates the long-standing drive for innovation within the Group and by 2024, we plan to identify how drones will prove an efficient complementary way of carrying biological samples”.

Last week Cerba HealthCare Italia performed the first drone flight with biological samples embedded, involving some of the medical centers around the Metropolitan City of Milan, specifically in the two sites located in the cities of Opera and Rozzano” adds Stefano Massaro, Chief Executive Officer of Cerba HealthCare Italia. “We are dealing with the first air transport of blood samples not yet tested, experimented by the use of a drone. The result of this adventure today makes us confident and eager to pursue the path of innovation as a landmark of a leading quality service for patients”.

About Cerba HealthCare

Cerba HealthCare, a leading global player in medical diagnostics, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.

Every day, on five continents, the Group's 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.

Cerba HealthCare, enlightening health.

Additional information is available at www.cerbahealthcare.com

Contacts

Press contact:
Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com

Cerba HealthCare Italia
Miriam Giudici
+34 63907608
mgiudici@eoipso.it

Cerba HealthCare


Release Versions

Contacts

Press contact:
Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com

Cerba HealthCare Italia
Miriam Giudici
+34 63907608
mgiudici@eoipso.it

Social Media Profiles
More News From Cerba HealthCare

Cerba HealthCare Changes Its Governance and Appoints Emmanuel Ligner Group Chief Executive Officer

ISSY LES MOULINEAUX, France--(BUSINESS WIRE)--Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group. The Group has also strengthened its Supervisory Board with the appointment of Paul Navarre as Chairman and the appointments of Dr. Nuala Murphy and Benoît Ribadeau-Dumas. Their international track records and deep healthcare expertise will support the Group’s expansion in Europe, Africa and North America in...

Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials

ISSY LES MOULINEAUX, France & LAVAL, Quebec--(BUSINESS WIRE)--Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services. CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosi...

Cerba and Taliaz to Leverage Artificial Intelligence and Genetics Expertise to Improve Patient Care Management in Depression

SAINT OUEN L’AUMÔNE, France & TEL AVIV, Israel--(BUSINESS WIRE)--Cerba, the foremost specialty clinical pathology reference, and Taliaz, an Israeli digital health company dedicated to improving mental health disorders, announced today a partnership to provide physicians with an AI-driven precision psychiatry solution that predicts treatment effectiveness in depression. By finding the right treatment from the very first prescription, the test helps physicians make the best therapeutic decision f...
Back to Newsroom